Professional Compounding Centers of America (PCCA) Invests $4 Million In San Diego-based Imprimis Pharmaceuticals; Agrees to Share Topical Drug-Delivery Knowledge and Technology to Bring New Medicines to Market
SOLANA BEACH, Calif., Sept. 7, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY: OTCQB) today announced a strategic development and investment agreement with Houston-based Professional Compounding Centers of America, Inc. (PCCA). The agreement will allow the companies to develop and share drug-formulation technology, with the goal of creating a new generation of treatments for muscle and joint pain, neuropathic pain and other conditions. PCCA also made a $4 million equity investment in Imprimis in a private transaction.
The agreement will give Imprimis exclusive non-PCCA-member access to PCCA's topical technologies and formulation know-how for delivering drugs directly through the skin. The arrangement is intended to identify development opportunities for new topical medications for new therapeutic applications.
Imprimis' lead drug candidate, Impracor™, a topical non-steroidal anti-inflammatory cream, is expected to enter Phase 3 clinical trials early in 2013. When approved for sale, Impracor would be applied to the site of muscle or joint pain, delivering a clinical dose of medication to the affected area without potential side effects such as stomach irritation or liver problems that have been associated with ingestible, non-steroidal, anti-inflammatory drugs.
The company has also developed Accudel™, a patented topical-delivery platform that can serve as a delivery vehicle for other medications.
To read the remainder of the article, click here.
No comments:
Post a Comment